Medy Tox (Korea) Today
| 086900 Stock | KRW 132,300 1,600 1.22% |
PerformanceInsignificant
| Odds Of DistressLow
|
Medy Tox is trading at 132300.00 as of the 18th of March 2025, a 1.22 percent increase since the beginning of the trading day. The stock's open price was 130700.0. Medy Tox has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Medy-Tox Inc., a biopharmaceutical company, develops, manufactures, markets, and sells botulinum toxin and hyaluronic acid dermal filler products primarily in South Korea. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea. The company has 5.44 M outstanding shares. More on Medy Tox
Moving against Medy Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Medy Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Medy Tox's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Medy Tox or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) |
Medy Tox (086900) is traded on KOSDAQ in Korea and employs 577 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 1 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medy Tox's market, we take the total number of its shares issued and multiply it by Medy Tox's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Medy Tox operates under Biotechnology sector and is part of Health Care industry. The entity has 5.44 M outstanding shares.
Medy Tox has accumulated about 71.77 B in cash with 19.97 B of positive cash flow from operations.
Check Medy Tox Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Medy Tox is W1 Trillion. Medy Tox holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with substantial debt, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.
Check Medy Ownership Details
Medy Tox Risk Profiles
Although Medy Tox's alpha and beta are two of the key measurements used to evaluate Medy Tox's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.95 | |||
| Semi Deviation | 2.61 | |||
| Standard Deviation | 3.06 | |||
| Variance | 9.38 |
Medy Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Medy Tox without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Medy Tox Corporate Management
Elected by the shareholders, the Medy Tox's board of directors comprises two types of representatives: Medy Tox inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medy. The board's role is to monitor Medy Tox's management team and ensure that shareholders' interests are well served. Medy Tox's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medy Tox's outside directors are responsible for providing unbiased perspectives on the board's policies.
| HeeSeok Joo | Managing Division | Profile | |
| SeungBum Park | Head Director | Profile | |
| HyunHo Jung | CEO Director | Profile | |
| YongIn Kim | Managing Devel | Profile | |
| KiHyuk Yang | MD Laboratory | Profile | |
| Lopez Michael | Managing Office | Profile | |
| WooSun Lee | Director Department | Profile |
Other Information on Investing in Medy Stock
Medy Tox financial ratios help investors to determine whether Medy Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medy with respect to the benefits of owning Medy Tox security.